Can taking nicorandil during heart surgery improve blood flow for STEMI patients?
For STEMI patients undergoing primary PCI (the standard emergency procedure to open a blocked artery), the main goal is to restore blood flow to the heart muscle. However, even after the large artery is opened, tiny blood vessels (the microcirculation) may not work well, a condition called microvascular dysfunction. Nicorandil is a drug that widens blood vessels and opens potassium channels in heart cells. A recent randomized trial tested whether giving nicorandil directly into the coronary artery during PCI could improve blood flow at the microvascular level. The short answer: the trial found that nicorandil improved several measures of blood flow and reduced microvascular resistance, suggesting it may help protect the heart during reperfusion.
What the research says
A 2024 prospective, single-center randomized trial studied 63 first-episode STEMI patients undergoing primary PCI 1. Patients were randomly assigned to receive either intracoronary nicorandil (2 mg after the guidewire crossed the blockage) or standard PCI alone 1. The primary endpoint was a wire-free measure of microvascular function called angiographic microcirculatory resistance (AMR). The nicorandil group had significantly better final AMR values, indicating less microvascular resistance 1. Secondary outcomes also favored nicorandil: the drug improved Thrombolysis in Myocardial Infarction (TIMI) flow grade (a standard measure of how well blood moves through the artery), reduced the rate of no-reflow (a dangerous condition where blood fails to reach the heart muscle despite the artery being open), and improved ST-segment resolution on the ECG (a sign of better tissue-level reperfusion) 1. These findings suggest that nicorandil can improve blood flow not only in the main artery but also in the tiny vessels that nourish the heart muscle. The trial did not report long-term clinical outcomes, so it remains unclear whether these short-term improvements translate into fewer heart attacks or deaths. Other research in STEMI patients has focused on different drugs and strategies: for example, a phase 2 trial is testing pre-hospital glucocorticoids to reduce reperfusion injury 7, and a meta-analysis found that many STEMI guideline recommendations are based on moderate or low-quality evidence 6. This highlights that while nicorandil shows promise, more studies are needed to confirm its benefits and to understand how it fits with other treatments.
What to ask your doctor
- Is intracoronary nicorandil available at our hospital during primary PCI for STEMI?
- What are the potential risks or side effects of using nicorandil during heart surgery or PCI?
- How does nicorandil compare with other drugs used to improve blood flow, such as adenosine or nitroprusside?
- Are there any ongoing trials or new evidence on nicorandil for STEMI that might affect my care?
- Could my specific heart condition or other medications make nicorandil more or less suitable for me?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.